Akebia Therapeutics, Inc. (NASDAQ:AKBA) has earned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.38.
Several equities research analysts recently commented on the company. BTIG Research assumed coverage on Akebia Therapeutics in a research report on Thursday. They set a “buy” rating and a $30.00 target price on the stock. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a report on Wednesday, August 9th. Finally, Royal Bank Of Canada initiated coverage on Akebia Therapeutics in a report on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 price target on the stock.
In other news, SVP Michel Dahan sold 1,398 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $19.64, for a total value of $27,456.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 7,586 shares of company stock worth $147,289 in the last 90 days. Corporate insiders own 7.95% of the company’s stock.
Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $15.40 on Thursday. Akebia Therapeutics has a 52-week low of $7.78 and a 52-week high of $20.25.
Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. The company had revenue of $41.28 million for the quarter, compared to analyst estimates of $34.00 million. equities analysts expect that Akebia Therapeutics will post -2.25 EPS for the current year.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.